

***Fiscal Year 2023 Department of Defense Lung Cancer Research Program (LCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Career Development Award Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-LCRP-CDA</p>	<p>Principal Investigator (PI)</p> <ul style="list-style-type: none"> • Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment (or equivalent). • Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs. • Must not have received more than \$300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants. <p>Mentor</p> <ul style="list-style-type: none"> • At or above the level of Associate Professor (or equivalent). • Must have a strong publication and funding record in lung cancer research. 	<ul style="list-style-type: none"> • Supports early-career, independent researchers to conduct research under the mentorship of an experienced lung cancer researcher. • Emphasis on research with high potential impact. • Clinical trials are not allowed. • Career development plan is required with appropriate mentor guidance. • Preliminary data are not required. • Relevance to military health is strongly encouraged. 	<ul style="list-style-type: none"> • Maximum funding of \$375,000 in direct costs (plus indirect costs). • Period of performance not to exceed 3 years. 	<p>Pre-Application (Letter of Intent): May 2, 2023 5:00 p.m. Eastern time (ET) Letter of Intent is required.</p> <p>Application: May 23, 2023 11:59 p.m. ET</p>
<p>Concept Award Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions 	<p>Investigators at all academic levels.</p>	<ul style="list-style-type: none"> • Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer. • Emphasis on innovative concept or untested theory. 	<ul style="list-style-type: none"> • Maximum funding of \$100,000 in direct costs (plus indirect costs). • Period of performance not to exceed 1 year. 	<p>Pre-Application (Letter of Intent): May 2, 2023 5:00 p.m. ET Letter of Intent is required.</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Grants.gov Funding Opportunity Number: HT9425-23-LCRP-CA</p>		<ul style="list-style-type: none"> • Research involving human subjects or specimens must be either exempt under Title 32, Code of Federal Regulations (CFR), Part 219, Section 104(d) (32 CFR 219.104[d]) or eligible for expedited review (21 CFR 56.110). • Clinical trials are not allowed. • Preliminary data are not required. • Relevance to military health is strongly encouraged. • <i>Care Delivery and Health Disparity category</i> must address one or more of the Disparities, Health Outcomes and Survivorship Areas of Emphasis. • <i>Cancer Research Continuum category</i> must address at least one or more of the nine cancer continuum-focused Areas of Emphasis. 		<p>Application: May 23, 2023 11:59 p.m. ET</p>
<p>Idea Development Award Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-LCRP-IDA</p>	<p>Established Investigators Independent investigators at or above the level of an Assistant Professor (or equivalent).</p> <p>New Investigators Investigators must meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have not previously received an LCRP Idea Development Award. • Are within 10 years of first faculty appointment (or equivalent). 	<ul style="list-style-type: none"> • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research. • Emphasis is on innovation and impact. • New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers. • Clinical trials are not allowed. • Preliminary data are required. • Relevance to military health is strongly encouraged. 	<ul style="list-style-type: none"> • Maximum funding of \$525,000 in direct costs (plus indirect costs). • Period of performance should not exceed 3 years. 	<p>Pre-Application (Preproposal): May 10, 2023 5:00 p.m. ET Preproposal is required; application submission is by invitation only.</p> <p>Application: August 3, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Patient-Centered Outcomes and Survivorship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-LCRP-PCOSA</p>	<p>Independent investigators with a faculty-level appointment (or equivalent)</p>	<ul style="list-style-type: none"> • Supports high-reward studies that span the spectrum of behavioral health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions and examining the physical, psychological, social, and economic effects of lung cancer. • Must address at least one area of emphasis in the Disparities or Health Outcomes/Survivorship categories. • Preliminary data are required. • Pilot clinical trials are allowed. • Relevance to military health is strongly encouraged. 	<ul style="list-style-type: none"> • Maximum funding of \$650,000 in direct costs (plus indirect costs). • Period of performance should not exceed 3 years. 	<p>Pre-Application (Letter of Intent): July 20, 2023 5:00 p.m. Eastern time (ET) Letter of Intent is required.</p> <p>Application: August 10, 2023 11:59 p.m. ET</p>
<p>Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-LCRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. • This mechanism is intended to fund a broad range of translational studies with two different funding levels. The following are general examples, although not all-inclusive, of the type of research projects that would be appropriate to propose under the current program announcement: <p>Funding Level 1:</p> <ul style="list-style-type: none"> ○ Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts 	<p>Level 1</p> <ul style="list-style-type: none"> • Maximum funding of \$900,000 in direct costs (plus indirect costs). • Period of performance should not exceed 3 years. <p>Level 2 – Clinical Trial Option</p> <ul style="list-style-type: none"> • Maximum funding of \$1,200,000 in direct costs (plus indirect costs). • Period of performance should not exceed 4 years. 	<p>Pre-Application (Preproposal): May 10, 2023 5:00 p.m. ET</p> <p>Preproposal is required; application submission is by invitation only.</p> <p>Application: August 3, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> ○ Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission ○ Correlative studies that are associated with an open/ongoing or completed clinical trial ○ Projects that develop endpoints for clinical trials <p>Funding Level 2:</p> <ul style="list-style-type: none"> ○ Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research <ul style="list-style-type: none"> ● Preliminary lung cancer relevant data are required. ● Relevance to military health is strongly encouraged. <p>Funding Level 1</p> <ul style="list-style-type: none"> ● Clinical trials are not allowed. <p>Funding Level 2</p> <ul style="list-style-type: none"> ● Supports translational studies that include a pilot/proof-of-principle clinical trial. ● Patient research advocate involvement is encouraged. 		